Concepts (179)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Radiology | 5 | 2019 | 97 | 1.410 |
Why?
|
| Positron-Emission Tomography | 8 | 2021 | 160 | 1.090 |
Why?
|
| Fluorodeoxyglucose F18 | 7 | 2021 | 81 | 1.040 |
Why?
|
| Nuclear Medicine | 4 | 2021 | 9 | 0.830 |
Why?
|
| Radionuclide Imaging | 6 | 2021 | 166 | 0.790 |
Why?
|
| Tomography, X-Ray Computed | 10 | 2021 | 2324 | 0.730 |
Why?
|
| Radiopharmaceuticals | 8 | 2021 | 114 | 0.710 |
Why?
|
| Internship and Residency | 5 | 2016 | 596 | 0.700 |
Why?
|
| Education, Medical, Graduate | 4 | 2019 | 214 | 0.680 |
Why?
|
| Accreditation | 5 | 2021 | 72 | 0.670 |
Why?
|
| Indium Radioisotopes | 3 | 2013 | 19 | 0.600 |
Why?
|
| Clinical Competence | 2 | 2016 | 657 | 0.570 |
Why?
|
| Faculty, Medical | 3 | 2019 | 110 | 0.570 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 3 | 2013 | 137 | 0.540 |
Why?
|
| Radiologists | 1 | 2016 | 35 | 0.540 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2021 | 300 | 0.510 |
Why?
|
| Antibodies, Monoclonal | 3 | 2013 | 511 | 0.490 |
Why?
|
| Quality Improvement | 1 | 2016 | 413 | 0.420 |
Why?
|
| Sarcoidosis | 2 | 2009 | 77 | 0.410 |
Why?
|
| Neuroendocrine Tumors | 1 | 2021 | 10 | 0.400 |
Why?
|
| Chylous Ascites | 1 | 2021 | 11 | 0.400 |
Why?
|
| Prostatic Neoplasms | 3 | 2013 | 778 | 0.390 |
Why?
|
| Organometallic Compounds | 1 | 2021 | 95 | 0.380 |
Why?
|
| Diuretics | 1 | 2021 | 97 | 0.380 |
Why?
|
| Laboratories | 1 | 2021 | 44 | 0.370 |
Why?
|
| Radiation Exposure | 1 | 2021 | 84 | 0.360 |
Why?
|
| Program Development | 2 | 2019 | 240 | 0.360 |
Why?
|
| Neoplasm Staging | 3 | 2014 | 800 | 0.350 |
Why?
|
| Lung Neoplasms | 2 | 2021 | 1173 | 0.340 |
Why?
|
| Leadership | 2 | 2019 | 136 | 0.340 |
Why?
|
| Budgets | 1 | 2019 | 12 | 0.340 |
Why?
|
| Fasting | 1 | 2009 | 75 | 0.330 |
Why?
|
| Biomedical Research | 2 | 2016 | 310 | 0.300 |
Why?
|
| Cardiomyopathies | 1 | 2009 | 167 | 0.300 |
Why?
|
| Fractures, Bone | 2 | 2012 | 132 | 0.290 |
Why?
|
| Tomography, Emission-Computed | 3 | 2007 | 40 | 0.290 |
Why?
|
| Gastric Emptying | 1 | 2017 | 24 | 0.290 |
Why?
|
| Hydrothorax | 1 | 2016 | 7 | 0.280 |
Why?
|
| Peritoneum | 1 | 2016 | 27 | 0.270 |
Why?
|
| Competency-Based Education | 1 | 2016 | 32 | 0.260 |
Why?
|
| Humans | 29 | 2021 | 68618 | 0.260 |
Why?
|
| End Stage Liver Disease | 1 | 2016 | 60 | 0.260 |
Why?
|
| Multimodal Imaging | 2 | 2014 | 62 | 0.250 |
Why?
|
| School Admission Criteria | 2 | 2015 | 36 | 0.240 |
Why?
|
| Guideline Adherence | 1 | 2017 | 287 | 0.240 |
Why?
|
| Databases, Factual | 1 | 2017 | 622 | 0.230 |
Why?
|
| Radiosurgery | 1 | 2014 | 66 | 0.230 |
Why?
|
| Pelvic Neoplasms | 1 | 2013 | 13 | 0.220 |
Why?
|
| Organizational Objectives | 1 | 2012 | 70 | 0.210 |
Why?
|
| Cultural Diversity | 1 | 2012 | 67 | 0.200 |
Why?
|
| Ventriculoperitoneal Shunt | 1 | 2011 | 16 | 0.200 |
Why?
|
| Breast Implants | 1 | 2011 | 18 | 0.200 |
Why?
|
| Absorptiometry, Photon | 1 | 2012 | 83 | 0.200 |
Why?
|
| Diphosphonates | 1 | 2012 | 39 | 0.200 |
Why?
|
| Schools, Medical | 1 | 2012 | 157 | 0.190 |
Why?
|
| Curriculum | 3 | 2016 | 575 | 0.190 |
Why?
|
| Minority Groups | 1 | 2012 | 197 | 0.190 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2013 | 239 | 0.190 |
Why?
|
| Cryosurgery | 1 | 2010 | 53 | 0.180 |
Why?
|
| Salvage Therapy | 1 | 2010 | 82 | 0.180 |
Why?
|
| Lymphatic Metastasis | 2 | 2013 | 274 | 0.180 |
Why?
|
| Retrospective Studies | 7 | 2021 | 7277 | 0.170 |
Why?
|
| Awards and Prizes | 1 | 2019 | 27 | 0.170 |
Why?
|
| Male | 15 | 2021 | 37321 | 0.160 |
Why?
|
| Adult | 9 | 2021 | 21403 | 0.150 |
Why?
|
| Radiography | 2 | 2016 | 572 | 0.150 |
Why?
|
| Myocardial Perfusion Imaging | 1 | 2008 | 100 | 0.150 |
Why?
|
| United States | 6 | 2021 | 7367 | 0.150 |
Why?
|
| Job Description | 1 | 2007 | 23 | 0.140 |
Why?
|
| Allied Health Occupations | 1 | 2007 | 11 | 0.140 |
Why?
|
| Technology, Radiologic | 1 | 2006 | 7 | 0.140 |
Why?
|
| Allied Health Personnel | 1 | 2007 | 37 | 0.140 |
Why?
|
| Credentialing | 1 | 2006 | 23 | 0.140 |
Why?
|
| Middle Aged | 10 | 2021 | 21147 | 0.140 |
Why?
|
| Lymph Nodes | 2 | 2021 | 258 | 0.140 |
Why?
|
| Medicine | 1 | 2006 | 52 | 0.140 |
Why?
|
| Specialization | 1 | 2006 | 66 | 0.140 |
Why?
|
| Feedback | 1 | 2016 | 90 | 0.140 |
Why?
|
| Gallium Radioisotopes | 2 | 2007 | 5 | 0.140 |
Why?
|
| Extravasation of Diagnostic and Therapeutic Materials | 1 | 2006 | 7 | 0.140 |
Why?
|
| Professional Competence | 1 | 2007 | 100 | 0.140 |
Why?
|
| Guidelines as Topic | 1 | 2006 | 123 | 0.130 |
Why?
|
| Kidney Diseases, Cystic | 1 | 2006 | 31 | 0.130 |
Why?
|
| Physicians | 1 | 2019 | 324 | 0.130 |
Why?
|
| Sexism | 1 | 2015 | 11 | 0.130 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2006 | 110 | 0.130 |
Why?
|
| Sensitivity and Specificity | 3 | 2013 | 1753 | 0.120 |
Why?
|
| Seminoma | 1 | 2004 | 6 | 0.120 |
Why?
|
| Education, Medical | 1 | 2006 | 147 | 0.120 |
Why?
|
| Iodine Radioisotopes | 1 | 2005 | 119 | 0.120 |
Why?
|
| Mediastinal Neoplasms | 1 | 2004 | 27 | 0.120 |
Why?
|
| Kidney Neoplasms | 1 | 2006 | 206 | 0.120 |
Why?
|
| Consumer Behavior | 1 | 2005 | 68 | 0.120 |
Why?
|
| Program Evaluation | 1 | 2016 | 502 | 0.120 |
Why?
|
| Thyroid Neoplasms | 1 | 2005 | 68 | 0.120 |
Why?
|
| Ilium | 1 | 2003 | 16 | 0.110 |
Why?
|
| Heart | 1 | 2008 | 850 | 0.110 |
Why?
|
| Musculoskeletal Diseases | 1 | 2004 | 45 | 0.110 |
Why?
|
| Diagnostic Imaging | 1 | 2004 | 201 | 0.110 |
Why?
|
| Environmental Exposure | 1 | 2005 | 269 | 0.110 |
Why?
|
| Ambulatory Care | 1 | 2005 | 340 | 0.110 |
Why?
|
| Coronary Artery Disease | 1 | 2008 | 696 | 0.100 |
Why?
|
| Aged | 7 | 2014 | 14862 | 0.100 |
Why?
|
| Myocardium | 1 | 2008 | 1204 | 0.100 |
Why?
|
| Octreotide | 1 | 2021 | 21 | 0.100 |
Why?
|
| Paracentesis | 1 | 2021 | 25 | 0.100 |
Why?
|
| Myositis | 1 | 2001 | 24 | 0.100 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2021 | 38 | 0.100 |
Why?
|
| Prostate | 2 | 2013 | 116 | 0.100 |
Why?
|
| Reproducibility of Results | 2 | 2014 | 2077 | 0.100 |
Why?
|
| Technetium Tc 99m Mertiatide | 1 | 2021 | 2 | 0.100 |
Why?
|
| Technetium Tc 99m Pentetate | 1 | 2021 | 6 | 0.100 |
Why?
|
| Reference Standards | 1 | 2021 | 115 | 0.100 |
Why?
|
| South Carolina | 3 | 2015 | 2752 | 0.090 |
Why?
|
| Head and Neck Neoplasms | 1 | 2006 | 561 | 0.090 |
Why?
|
| Female | 8 | 2019 | 38074 | 0.090 |
Why?
|
| Subtraction Technique | 1 | 2009 | 12 | 0.090 |
Why?
|
| Students, Medical | 2 | 2016 | 210 | 0.080 |
Why?
|
| Costs and Cost Analysis | 1 | 2019 | 193 | 0.080 |
Why?
|
| Image Enhancement | 1 | 2009 | 143 | 0.080 |
Why?
|
| Pilot Projects | 1 | 2021 | 1342 | 0.070 |
Why?
|
| Neoplasm Metastasis | 2 | 2011 | 306 | 0.070 |
Why?
|
| Single Photon Emission Computed Tomography Computed Tomography | 1 | 2016 | 9 | 0.070 |
Why?
|
| Diagnosis, Differential | 3 | 2006 | 1140 | 0.070 |
Why?
|
| Patient Care Planning | 1 | 2016 | 108 | 0.060 |
Why?
|
| Aged, 80 and over | 3 | 2011 | 4848 | 0.060 |
Why?
|
| Licensure | 1 | 2015 | 18 | 0.060 |
Why?
|
| Organizational Case Studies | 1 | 2015 | 53 | 0.060 |
Why?
|
| Informed Consent | 1 | 2016 | 127 | 0.060 |
Why?
|
| Mentors | 1 | 2015 | 81 | 0.060 |
Why?
|
| Teaching | 1 | 2016 | 169 | 0.060 |
Why?
|
| Career Choice | 1 | 2015 | 98 | 0.060 |
Why?
|
| Problem-Based Learning | 1 | 2015 | 72 | 0.060 |
Why?
|
| Early Diagnosis | 1 | 2014 | 122 | 0.060 |
Why?
|
| Educational Measurement | 1 | 2016 | 254 | 0.060 |
Why?
|
| Postoperative Period | 1 | 2014 | 238 | 0.060 |
Why?
|
| Physician-Patient Relations | 1 | 2016 | 261 | 0.060 |
Why?
|
| Patient Care Team | 1 | 2016 | 311 | 0.060 |
Why?
|
| Communication | 1 | 2016 | 329 | 0.050 |
Why?
|
| Seminal Vesicles | 1 | 2011 | 7 | 0.050 |
Why?
|
| Fellowships and Scholarships | 1 | 2012 | 127 | 0.050 |
Why?
|
| Femur | 1 | 2012 | 113 | 0.050 |
Why?
|
| Surveys and Questionnaires | 1 | 2019 | 2800 | 0.050 |
Why?
|
| Biopsy, Needle | 1 | 2010 | 191 | 0.040 |
Why?
|
| Prostate-Specific Antigen | 1 | 2010 | 138 | 0.040 |
Why?
|
| Disease-Free Survival | 1 | 2010 | 349 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2010 | 536 | 0.040 |
Why?
|
| Prognosis | 1 | 2014 | 2093 | 0.040 |
Why?
|
| Healthcare Disparities | 1 | 2012 | 378 | 0.040 |
Why?
|
| Follow-Up Studies | 1 | 2014 | 3259 | 0.040 |
Why?
|
| Technetium Tc 99m Exametazime | 1 | 2007 | 9 | 0.040 |
Why?
|
| Societies, Medical | 1 | 2019 | 403 | 0.040 |
Why?
|
| Equipment Design | 1 | 2008 | 500 | 0.040 |
Why?
|
| Leukocytes | 1 | 2007 | 99 | 0.040 |
Why?
|
| Time Factors | 1 | 2014 | 4655 | 0.030 |
Why?
|
| Diverticulum | 1 | 2006 | 29 | 0.030 |
Why?
|
| Hemodynamics | 1 | 2008 | 705 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2013 | 3705 | 0.030 |
Why?
|
| Relative Biological Effectiveness | 1 | 2005 | 10 | 0.030 |
Why?
|
| Body Burden | 1 | 2005 | 27 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2006 | 2223 | 0.030 |
Why?
|
| Etoposide | 1 | 2004 | 64 | 0.030 |
Why?
|
| Radiation Protection | 1 | 2005 | 71 | 0.030 |
Why?
|
| Cisplatin | 1 | 2004 | 192 | 0.030 |
Why?
|
| Biopsy | 1 | 2006 | 540 | 0.030 |
Why?
|
| Health Personnel | 1 | 2006 | 286 | 0.030 |
Why?
|
| Osteomyelitis | 1 | 2004 | 40 | 0.030 |
Why?
|
| Prosthesis-Related Infections | 1 | 2004 | 70 | 0.030 |
Why?
|
| Arthroplasty, Replacement | 1 | 2004 | 48 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2015 | 1040 | 0.030 |
Why?
|
| Bone Neoplasms | 1 | 2003 | 100 | 0.030 |
Why?
|
| Esophageal Neoplasms | 1 | 2003 | 150 | 0.030 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2004 | 468 | 0.020 |
Why?
|
| Lymphoma | 1 | 2001 | 116 | 0.020 |
Why?
|
| Leg | 1 | 2001 | 191 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2004 | 1330 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2005 | 2007 | 0.020 |
Why?
|
| Risk Factors | 1 | 2005 | 5731 | 0.020 |
Why?
|
| Adolescent | 1 | 2005 | 8912 | 0.010 |
Why?
|